ReiThera Announces its GRAd-COV2 COVID-19 Vaccine Candidate is Well Tolerated and Induces Clear Immune Responses in Healthy Subjects Aged 18-55 Years Phase 1 Trial to Advance into Elderly Subjects Aged 65-85 Years

ROME, Italy, November 24th, 2020 – ReiThera Srl, a biotech company dedicated to the technology development, GMP manufacturing and clinical translation of genetic vaccines and medicinal products [...]

page 1 of 3